(firstQuint)Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer.

 This phase 2 study of donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is to assess efficacy and safety in patients with 131I-refractory/resistant differentiated thyroid cancer.

The study is a randomised,multicentre,open-label study.

.

 Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer@highlight

Donafenib for advanced 131I-refractory/resistant differentiated thyroid cancer(DTC).

